Mirati Therapeutics reports Q4 EPS ($3.51), consensus ($3.55)

Reports Q4 revenue $934M, consensus $2.27M. Cash, cash equivalents, and short-term investments of approximately $1.1B as of December 31, 2022. "2022 was a momentous year for Mirati, culminating in the approval and launch of KRAZATI(TM) as a treatment for patients with locally advanced or metastatic non-small cell lung cancer with a KRASG12C mutation. We believe this is the first of several potentially best-in-class products on the horizon for Mirati," said David Meek, CEO. "In addition to the approval of KRAZATITM, in 2022 we advanced MRTX1719 and MRTX0902 into clinical trials and filed an Investigational New Drug application for MRTX1133. These accomplishments bring us closer to realizing our vision to unlock the promise of a life beyond cancer. We look ahead to 2023 with excitement as the company enters a new phase of commercialization from a strong financial position."